The Pink Pill Documentary Exposes Bias in Female Sexual Health Treatment
In the documentary The Pink Pill: Sex, Drugs & Who Has Control, the fight to provide access to the so-called 'female Viagra' reveals an industry that persistently discounts the needs of women. The film delves into the journey of flibanserin, a drug developed to treat low female libido, and uncovers a landscape marked by regulatory hurdles, pharmaceutical greed, and societal indifference toward female desire.
A Personal Struggle with Lost Libido
Barbara Gattuso, a woman who had enjoyed a fulfilling sex life for decades, experienced a sudden loss of desire during her perimenopausal years. She describes it as a mysterious evaporation, like "somebody pulled the plug." In the late 2000s, she joined a clinical trial for flibanserin, originally an antidepressant that showed promise for enhancing female libido by targeting neurotransmitters in the brain's "sex center." Dr. Irwin Goldstein, a key consultant on Viagra, filmed Gattuso during the trial, where she expressed feeling "phenomenal" and like a "new woman," reigniting her passion and chasing her husband around again.
Regulatory Roadblocks and Gender Bias
Despite early optimism, the path to FDA approval for flibanserin, rebranded as Addyi, was fraught with challenges. Approved in August 2015 for premenopausal women with Hypoactive Sexual Desire Disorder (HSDD), and later for postmenopausal women, the drug remains largely unknown. Director Aisling Chin-Yee noted her own ignorance, stating, "I had never heard of this drug" before making the film, highlighting a broader medical disinterest in female sexuality beyond reproduction.
The documentary points out that most medical school curricula lack sections on female sexual health, libido, or clitoral anatomy. While Viagra was quickly embraced as a breakthrough for men's physical issues in 1998, discussions around female libido stagnated, often dismissed as "complicated." The FDA assigned Addyi's review to its urology division, more suited to Viagra's mechanism, and initially rejected it due to side effects like dizziness and nausea, questioning whether desire was "worth it" for women.
The Fight for Approval and Cultural Backlash
Cindy Eckert, a pharmaceutical entrepreneur, bought flibanserin for $5 million in 2011 after Boehringer Ingelheim abandoned it. She renamed it Addyi, inspired by a character from Grey's Anatomy, and through her company, Sprout Pharmaceuticals, completed trials showing improved sexual drive for women with HSDD. However, the FDA's approval process was marred by paternalistic attitudes, with concerns about side effects overshadowing benefits, such as an increase of one "successful sexual event" per month.
The film archives the cultural wars of the 2010s, where Addyi faced patronizing jokes and skepticism. Some critics argued HSDD was a fictional condition, medicalizing low libido for profit. Dr. Anita Clayton recalled the FDA's paternalistic worry that women might fall asleep while driving their kids to school after taking the drug, a concern never raised for male treatments.
Post-Approval Challenges and Double Standards
After much debate, the FDA approved Addyi in 2015 but with a black box warning, the most severe caution, requiring doctors and pharmacists to pass tests and patients to sign pledges avoiding alcohol. In contrast, Viagra merely recommends avoiding alcohol. Eckert sold Sprout to Valeant for $1 billion, but the company doubled the price to $800 per prescription, making it unaffordable, and eventually shelved it in 2017.
Eckert later repurchased Addyi, but it remains under a cloud of warnings. Proponents highlight a double standard: 26 drugs are approved for male sexual dysfunction, yet Addyi faces disproportionate scrutiny. Chin-Yee emphasized, "You should be able to have that discussion with your own body and your own physician, rather than somebody just removing it as an option for you."
Broader Implications for Women's Rights
The documentary connects the struggle for Addyi to larger issues of bodily autonomy in a post-Roe world, where reproductive rights are under attack and healthcare for marginalized groups is criminalized. Chin-Yee argues that the right to sexual pleasure is not frivolous; it is intertwined with other freedoms being eroded in the United States. The film concludes that choice, whether for abortion or orgasm, is fundamental and consequential.
The Pink Pill is now available on Paramount+, offering a compelling look at how female desire continues to be undervalued in medicine and society.
